|
 |
adefovir dipivoxilThis page contains recent news articles, when available, and an overview of adefovir dipivoxil but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.Hepsera(R) (adefovir dipivoxil) sales were $83.0 million for the first quarter of 2008, a 16 percent increase from $71.3 million in the first quarter of Centre Daily Times, Treatment of the HBV-Infected Patient: When to Start, When to Stop ... - Feb 27, 2008 Sustained biochemical and virological remission after discontinuation of 4 to5 years of adefovir dipivoxil (ADV) treatment in HBeAg-negative chronic Medscape (subscription) Gilead Sciences Announces Fourth Quarter and Full Year 2007 ... - Jan 23, 2008 Hepsera for Chronic Hepatitis B Hepsera® (adefovir dipivoxil) sales were $76.9 million for the fourth quarter of 2007, a 17 percent increase from $65.9 WELT ONLINE, Gilead Sciences Announces Fourth Quarter and Full Year 2007 ... - Jan 24, 2008 Hepsera® (adefovir dipivoxil) sales were $76.9 million for the fourth quarter of 2007, a 17 percent increase from $65.9 million in the fourth quarter of Lifescience-online, Telbivudine May Be More Effective Than Lamivudine for Chronic ... - 19 Dec 2007 Current options for the treatment of chronic HBV infection include multiple types of interferon, adefovir dipivoxil, and lamivudine. Medscape (subscription) Evolution of Therapy for Chronic Hepatitis B: Progressing from the ... - Dec 3, 2007 In this issue, Chan and colleagues (17) compared the antiviral efficacy of telbivudine and adefovir dipivoxil at 24 weeks of therapy. Annals of Internal Medicine 2007 Annual General Meeting Presentation - Dec 10, 2007 Development Trails w/SFDA Launch YouHeDing (anti-HBV drug) Adefovir Dipivoxil Approved 2003 2005 2007 Anti-HBV drug program L-nucleotide Pre-clinical Sydney Morning Herald, Gilead HIV Viread Bettered Gilead HBV Hepsera In Curing HBV - Nov 3, 2007 On the other hand, Gilead has another product Hepsera, or adefovir dipivoxil, which is already approved for treating the liver infection in adults. eFluxMedia Gilead Adds To Fibrotic Disease Pipeline In $202M Deal With LGLS - Nov 7, 2007 On the liver side, Gilead markets Hepsera (adefovir dipivoxil) for hepatitis B virus (HBV) infection and, earlier this year, reported promising top-line BioWorld Online, Gilead's drug promising in hepatitis B - Nov 6, 2007 By Staff Writer Studies 102 and 103 compare Viread to Gilead's Hepsera (adefovir dipivoxil) among patients with hbeag-negative (presumed pre-core mutant) Pharmaceutical Business Review Fewer Hepatitis B Patients Need Liver Transplants - Nov 5, 2007 The four antiviral medicines that are used to treat hepatitis B are adefovir dipivoxil, entecavir, lamivudine, and telbivudine. Associated Content, Gilead looks to put Viread up against B-MS' Baraclude as a ... - Nov 5, 2007 They compared Viread (tenofovir) to Hepsera (adefovir dipivoxil) among patients with hbeag-negative and hbeag-positive hepatitis B, respectively. Pharma Times (subscription), Gilead Sciences Says HBV Drug Viread Shows Superior Efficacy ... - Nov 2, 2007 Studies 102 and 103, which evaluate the safety and efficacy of once-daily Viread, compare Viread to Gilead's Hepsera or adefovir dipivoxil among patients RTT News, Gilead Announces 48-Week Data from Two Pivotal Phase III Studies ... - Nov 2, 2007 Studies 102 and 103 compare Viread to Gilead’s Hepsera ® (adefovir dipivoxil) among patients with hbeag-negative (presumed pre-core mutant) chronic Business Wire (press release), Nationwide Decrease in the Need for Liver Transplant - Nov 2, 2007 ...four oral antiviral medications have been approved by the Food and Drug Administration for treatment of hepatitis B: lamivudine, adefovir dipivoxil, Newswise (press release) Gilead Sciences Announces Third Quarter 2007 Financial Results - Oct 19, 2007 Hepsera(R) (adefovir dipivoxil) and ambisome(R) (amphotericin B) liposome for injection also experienced solid sales growth compared to the same quarter PharmaLive.com (press release), Gilead Asks Viread Approval In US, Europe Against HBV - Oct 13, 2007 ...based Gilead's Hepsera (adefovir dipivoxil). Top-line data were disclosed in June, and details are due at the annual meeting of the American Association for BioWorld Online, News From The Annals Of Internal Medicine - Oct 2, 2007 A 52-week, randomized trial involving 135 people with chronic hepatitis B virus (HBV) compared an older drug adefovir dipivoxil and a newer drug, Medical News Today (press release), Pharmasset Commences Dosing in Phase 3 Registration Studies of ... - Oct 1, 2007 ...trials designed to demonstrate the superiority of clevudine 30mg over Hepsera (adefovir dipivoxil) 10mg, each administered once-daily as monotherapy. CNNMoney.com Small Caps Monitor: SEA, CCY, MNC and AGX - Oct 3, 2007 The company said it has recruited staff to sell YouHeDing (adefovir dipivoxil) in key areas in China. "The patient population for hepatitis B virus (HBV) in ABN Newswire (press release), Gilead Sciences Marketing Applications In US And European Union ... - Oct 11, 2007 These studies evaluate the efficacy, safety and tolerability of Viread compared to Gilead's Hepsera or adefovir dipivoxil. Eugene Schiff, Chief of the RTT News, [an error occurred while processing this directive] [an error occurred while processing this directive] [an error occurred while processing this directive] [an error occurred while processing this directive] [an error occurred while processing this directive] [an error occurred while processing this directive] [an error occurred while processing this directive] [an error occurred while processing this directive] [an error occurred while processing this directive] [an error occurred while processing this directive] : |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines mongabay.com
COPYRIGHT 2007 MONGABAY.COM |